

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (currently amended) A pharmaceutical composition for sustained release, comprising: as active ingredient pitavastatin or a pharmaceutically acceptable salt thereof, wherein said composition comprising a core consisting of an inner phase ~~(internal)~~ and an outer phase ~~(external)~~ wherein the outer phase does not comprise a matrix former and wherein the core is first coated with a non functional film coat and then with an enteric coat.
2. (previously presented) The composition according to claim 1, wherein the amount of pitavastatin or pharmaceutically acceptable salt thereof is about 5-50 weight % of the core composition.
3. (previously presented) The composition according to claim 2 wherein the amount of pitavastatin or pharmaceutically acceptable salt thereof is about 5-50 weight % of the core composition.
4. (previously presented) The composition according to claim 1, wherein the amount of pitavastatin or pharmaceutically acceptable salt thereof is about 1-32 mg.
5. (previously presented) The composition according to claim 1, wherein the inner phase comprises a matrix former .
6. (previously presented) The composition according to claim 5, wherein the matrix former comprises one or more types of matrix former component having different viscosities.
7. (previously presented) The composition according to claim 5, wherein the matrix former is selected from the group consisting of polyethylene glycol, polyvinylpyrrolidone,

polyvinyl alcohol, hydrophilic polymers such as hydroxypropylcellulose, hydroxymethylcellulose, and hydroxypropylmethylcellulose.

8. (previously presented) The composition according to claim 7, wherein the matrix former is hydroxypropylmethylcellulose (HPMC).

9. (previously presented) The composition according to claim 8 wherein the amount of HPMC as a matrix former is about 1-60 weight % (based on the total core components).

10. (previously presented) The composition according to claim 9, wherein the matrix former of the inner phase has a viscosity of about 1 to about 100,000 cps.

11. (previously presented) The composition according to claim 9, wherein the matrix former of the inner phase has a viscosity of about 1 to about 500 cps.

12. (previously presented) The composition according to claim 1 wherein said composition comprises a stabilizer.

13. (previously presented) The composition according to claim 12, wherein the stabilizer is magnesium aluminometasilicate (neusilin).

14. (previously presented) The composition according to claim 13, wherein the amount of the stabilizer is about 1-15 weight % (based on the total core components).

15. (currently amended) The composition according to claim 1, wherein the non-functional coat consists of Hydroxypropylmethylcellulose, Polyethyleneglycol, titanium dioxide and talc.

16. (currently amended) The composition according to claim 1, wherein the amount of non functional film coat is used at about 4 mg of film coat per cm².

17. (previously presented) The composition according to claim 1, wherein the enteric coat consists of methacrylic copolymer, talc and polyethyleneglycol.

18 (currently amended) The composition according to claim 1, wherein the enteric coat is used at 4 to 6 mg polymer [[pro]] per cm².

19. (previously presented) A method of treatment of hyperlipidemia, hypercholesterolemia and atherosclerosis, as well as other diseases or conditions in which HMG-CoA reductase is implicated, comprising:

administering to a patient in need thereof a therapeutically effective amount of a composition according to claim 1.

20. (canceled)